IRX4204 A Phase II Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Parkinson’s Disease
Martin E. Sanders, M.D., Sichuan Provincial Neuroscience Society, 2023
IRX4204 – A Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Psoriasis and other Autoimmune Skin Diseases
Martin E. Sanders, M.D.
IRX4204 – A Phase II Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Neurodegenerative and Autoimmune Diseases
Martin E. Sanders, M.D., BIO International Convention, 2023
Io Therapeutics Phase II Clinical Stage and Preclinical Retinoid Compounds for Treatment of Cancers
Martin E. Sanders, M.D., BIO International Convention, 2023